Acute Vulvovaginal Candidiasis Treatment; Depends on the Severity and Frequency of the Infection
Acute Vulvovaginal Candidiasis Treatment
Acute vulvovaginal candidiasis is a yeast infection, which affects the vagina and tissues present at the opening of the vulva. Candidiasis is a fungal infection caused by yeast (type of fungus) called Candida, which is present in the human body. While, vulvovaginal candidiasis refers to the vaginal and vulval symptoms caused by Candida albicans. Candidiasis in the vagina is commonly called a vulvovaginal candidiasis or vaginal yeast infection. Symptoms of vulvovaginal candidiasis include external dysuria, dyspareunia, pruritus, vaginal soreness, and abnormal vaginal discharge.
Acute vulvovaginal candidiasis is commonly observed in
women in the reproductive age group. It is quite uncommon in prepubertal and/or
postmenopausal females. It can cause intense itchiness, inflammation, and a
thick, white discharge from a vagina. Fluconazole, clotrimazole, and nystatin
are some of the most commonly used drugs for the acute vulvovaginal candidiasis
treatment. Apart from these, other drugs such as Terconazole, Terbinafine,
Ketoconazole, and Miconazole are also available in the market for the acute
vulvovaginal candidiasis treatment.
The global
acute vulvovaginal candidiasis treatment is estimated to be valued at US$ 308.0 Mn in 2020 and is
expected to exhibit a CAGR of 3.0% over
the forecast period (2020-2027).
Vulvovaginal candidiasis is usually treated with
antifungal medication. The oral triterpenoid agent, ibrexafungerp, is the first
non-azole antifungal approved (by U.S. Food and Drug Administration) for
vulvovaginal candidiasis and the first drug approved in a new antifungal class
for vulvovaginal candidiasis in more than 20 years. Some women with infections
opt for treatment with over-the-counter (OTC) medications, which generally are
highly effective for candidiasis. Taking antifungal drug for 3 to 7 days
usually clear a yeast infection.
A variety of factors can make a woman more susceptible
to Acute
Vulvovaginal Candidiasis Treatment,
such as estrogen, antibiotic use, a change in immune function, and a history of
recurrent infections with Candida. Some studies show that the presence of
yeasts in the vaginal mucosa, called a yeast layer, is a risk factor for
development of VVC. Over-the-counter creams and suppositories are often used to
treat this condition before seeking medical care. One should consult a doctor
immediately to be evaluated for other causes of vulvovaginal candidiasis.
Acute vulvovaginal candidiasis is a condition that
occurs in up to 3 out of 4 women at some point during their life and can be
triggered by a variety of factors. The condition usually responds quickly to
antifungal therapy and has a high rate of cure, although some women may develop
recurrent vulvovaginal candidiasis (RVVC), which is defined as four or more
episodes per year.
Comments
Post a Comment